1 |
PARP2
| [2] Base excision repair Base excision repair, Apoptosis | D09730
D09730
|
Olaparib
| [2] 86 86, 285 |
2 |
CA5B
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
3 |
CA5B
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
4 |
CHRM1
| [8] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02212
D02212
|
Ipratropium
| [2] 6 6, 86 |
5 |
CHRM2
| [6] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D02212
D02212
|
Ipratropium
| [2] 6 6, 86 |
6 |
CHRM3
| [11] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02212
D02212
|
Ipratropium
| [2] 6 6, 86 |
7 |
CHRM4
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D02212
D02212
|
Ipratropium
| [2] 6 6, 86 |
8 |
CHRM5
| [6] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D02212
D02212
|
Ipratropium
| [2] 6 6, 86 |
9 |
SLC22A12
| - | D01056
D01056
|
Benzbromarone
| [1] 86 86 |
10 |
PARP1
| [5] Base excision repair Base excision repair, NF-kappa B signaling pathway, Apoptosis, Necroptosis, Diabetic cardiomyopathy | D09730
D09730
|
Olaparib
| [2] 86 86, 285 |
11 |
ADRA1D
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
12 |
ADRA1D
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
13 |
ADRA1B
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
14 |
ADRA1B
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
15 |
ADRA1A
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00255
D00255
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
16 |
ADRA1A
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D03415
D03415
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
17 |
ADRB1
| [11] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00255
D00255
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
18 |
ADRB1
| [11] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00634
D00634
|
Bisoprolol
| [3] 67 67, 86, 113 |
19 |
ADRB1
| [11] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D02342
D02342
|
Bisoprolol
| [3] 67 67, 86, 113 |
20 |
ADRB1
| [11] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D03415
D03415
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
21 |
ADRB2
| [9] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00255
D00255
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
22 |
ADRB2
| [9] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147
D02147
|
Salbutamol
| [14] 3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 |
23 |
ADRB2
| [9] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D03415
D03415
|
Carvedilol
| [5] 6 6, 57, 86, 113, 210 |
24 |
CYP19A1
| [3] Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Ovarian steroidogenesis | D00960
D00960
|
Anastrozole
| [3] 78 78, 86, 193 |
25 |
ACE
| [6] Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00251
D00251
|
Captopril
| [8] 6 6, 17, 46, 86, 96, 97, 107, 271 |
26 |
NQO1
| [7] Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D00564
D00564
|
Warfarin
| [13] 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
27 |
NQO1
| [7] Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D01280
D01280
|
Warfarin
| [13] 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
28 |
NQO1
| [7] Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D08682
D08682
|
Warfarin
| [13] 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
29 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01348
D01348
|
Terguride
| [2] 51 51, 86 |
30 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D01462
D01462
|
Lisuride
| [2] 6 6, 86 |
31 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D08132
D08132
|
Lisuride
| [2] 6 6, 86 |
32 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D01462
D01462
|
Lisuride
| [2] 6 6, 86 |
33 |
DRD3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08132
D08132
|
Lisuride
| [2] 6 6, 86 |
34 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D01462
D01462
|
Lisuride
| [2] 6 6, 86 |
35 |
DRD4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Dopaminergic synapse | D08132
D08132
|
Lisuride
| [2] 6 6, 86 |
36 |
AGTR1
| [16] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00150
D00150
|
Angiotensin II
| [7] 17 17, 19, 46, 66, 86, 222, 224 |
37 |
AGTR1
| [16] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D02014
D02014
|
Angiotensin II
| [7] 17 17, 19, 46, 66, 86, 222, 224 |
38 |
AGTR2
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system | D00150
D00150
|
Angiotensin II
| [7] 17 17, 19, 46, 66, 86, 222, 224 |
39 |
AGTR2
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system | D02014
D02014
|
Angiotensin II
| [7] 17 17, 19, 46, 66, 86, 222, 224 |
40 |
EDNRA
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D01227
D01227
|
Bosentan
| [11] 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
41 |
EDNRA
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07077
D07077
|
Ambrisentan
| [7] 51 51, 84, 85, 86, 88, 210, 211 |
42 |
EDNRA
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07171
D07171
|
Sitaxentan
| [1] 86 86 |
43 |
EDNRA
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D07538
D07538
|
Bosentan
| [11] 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
44 |
EDNRA
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer | D10135
D10135
|
Macitentan
| [5] 51 51, 85, 86, 88, 210 |
45 |
EDNRB
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D01227
D01227
|
Bosentan
| [11] 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
46 |
EDNRB
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D07538
D07538
|
Bosentan
| [11] 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
47 |
EDNRB
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer | D10135
D10135
|
Macitentan
| [5] 51 51, 85, 86, 88, 210 |
48 |
EGFR
| [48] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D03455
D03455
|
Cetuximab
| [5] 34 34, 51, 86, 89, 331 |
49 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00966
D00966
|
Tamoxifen
| [4] 2 2, 86, 113, 227 |
50 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01161
D01161
|
Fulvestrant
| [2] 49 49, 86 |
51 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08409
D08409
|
Prasterone
| [6] 49 49, 53, 83, 86, 96, 113 |
52 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08559
D08559
|
Tamoxifen
| [4] 2 2, 86, 113, 227 |
53 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D00966
D00966
|
Tamoxifen
| [4] 2 2, 86, 113, 227 |
54 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D01161
D01161
|
Fulvestrant
| [2] 49 49, 86 |
55 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08409
D08409
|
Prasterone
| [6] 49 49, 53, 83, 86, 96, 113 |
56 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08559
D08559
|
Tamoxifen
| [4] 2 2, 86, 113, 227 |
57 |
FLT3
| [8] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia, Central carbon metabolism in cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
58 |
FLT3
| [8] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia, Central carbon metabolism in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
59 |
FLT4
| [8] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer, Breast cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
60 |
FLT4
| [8] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Pathways in cancer, Breast cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
61 |
BRD4
| - | D11131
D11131
|
Apabetalone
| [1] 86 86 |
62 |
CA14
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
63 |
CA14
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
64 |
MTOR
| [51] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| [41] 2 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
65 |
ABL1
| [11] ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D01441
D01441
|
Imatinib
| [12] 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
66 |
ABL1
| [11] ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08066
D08066
|
Imatinib
| [12] 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
67 |
ABL1
| [11] ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis | D08953
D08953
|
Nilotinib
| [5] 6 6, 8, 34, 51, 86 |
68 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| [19] 86 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
69 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473
D00473
|
Prednisone
| [20] 86 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
70 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00751
D00751
|
Methylprednisolone
| [19] 86 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
71 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00979
D00979
|
Methylprednisolone
| [19] 86 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
72 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05000
D05000
|
Methylprednisolone
| [19] 86 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
73 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05001
D05001
|
Methylprednisolone
| [19] 86 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
74 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05002
D05002
|
Methylprednisolone
| [19] 86 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
75 |
ANPEP
| [4] Glutathione metabolism Glutathione metabolism, Metabolic pathways, Renin-angiotensin system, Hematopoietic cell lineage | D00087
D00087
|
Ubenimex
| [1] 86 86 |
76 |
GUCY1A2
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D09572
D09572
|
Riociguat
| [6] 51 51, 84, 86, 88, 225, 299 |
77 |
GUCY1A1
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D09572
D09572
|
Riociguat
| [6] 51 51, 84, 86, 88, 225, 299 |
78 |
GUCY1B1
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Gap junction, Platelet activation, Circadian entrainment, Long-term depression, Oxytocin signaling pathway, Renin secretion, Salivary secretion | D09572
D09572
|
Riociguat
| [6] 51 51, 84, 86, 88, 225, 299 |
79 |
HMGCR
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D00434
D00434
|
Simvastatin
| [21] 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
80 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00300
D00300
|
Diphenhydramine
| [10] 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
81 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00669
D00669
|
Diphenhydramine
| [10] 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
82 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D02419
D02419
|
Diphenhydramine
| [10] 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
83 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03285
D03285
|
Diphenhydramine
| [10] 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
84 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03360
D03360
|
Diphenhydramine
| [10] 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
85 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D03854
D03854
|
Diphenhydramine
| [10] 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
86 |
HRH2
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion | D00318
D00318
|
Famotidine
| [7] 6 6, 46, 61, 86, 98, 107, 300 |
87 |
IL1R1
| [13] MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis | D02934
D02934
|
Anakinra
| [19] 2 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
88 |
IL6R
| [12] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | D02596
D02596
|
Tocilizumab
| [21] 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
89 |
AR
| [4] Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08409
D08409
|
Prasterone
| [6] 49 49, 53, 83, 86, 96, 113 |
90 |
CA13
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
91 |
CA13
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
92 |
KDR
| [10] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
93 |
KDR
| [10] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Proteoglycans in cancer, Fluid shear stress and atherosclerosis | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
94 |
KIT
| [11] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D01441
D01441
|
Imatinib
| [12] 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
95 |
KIT
| [11] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
96 |
KIT
| [11] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08066
D08066
|
Imatinib
| [12] 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
97 |
KIT
| [11] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
98 |
KIT
| [11] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D08953
D08953
|
Nilotinib
| [5] 6 6, 8, 34, 51, 86 |
99 |
MAP3K5
| [20] Platinum drug resistance Platinum drug resistance, MAPK signaling pathway, Sphingolipid signaling pathway, Protein processing in endoplasmic reticulum, Apoptosis, Tight junction, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - reactive oxygen species, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10988
D10988
|
Selonsertib
| [1] 86 86 |
100 |
NR3C2
| [1] Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption | D00443
D00443
|
Spironolactone
| [5] 86 86, 113, 210, 218, 225 |
101 |
ATP4A
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01984
D01984
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
102 |
ATP4A
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D04056
D04056
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
103 |
ATP4A
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
104 |
ATP4A
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D09339
D09339
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
105 |
ATP4B
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01984
D01984
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
106 |
ATP4B
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D04056
D04056
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
107 |
ATP4B
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
108 |
ATP4B
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D09339
D09339
|
Esomeprazole
| [8] 13 13, 46, 86, 98, 107, 113, 298, 299 |
109 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D00842
D00842
|
Morphine
| [6] 36 36, 46, 70, 85, 86, 298 |
110 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D02271
D02271
|
Morphine
| [6] 36 36, 46, 70, 85, 86, 298 |
111 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D08233
D08233
|
Morphine
| [6] 36 36, 46, 70, 85, 86, 298 |
112 |
PDGFRA
| [20] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D01441
D01441
|
Imatinib
| [12] 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
113 |
PDGFRA
| [20] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08066
D08066
|
Imatinib
| [12] 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
114 |
PDGFRA
| [20] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08953
D08953
|
Nilotinib
| [5] 6 6, 8, 34, 51, 86 |
115 |
PDGFRB
| [19] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
116 |
PDGFRB
| [19] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
117 |
PDGFRB
| [19] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer | D08953
D08953
|
Nilotinib
| [5] 6 6, 8, 34, 51, 86 |
118 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D00945
D00945
|
Pioglitazone
| [17] 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
119 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08378
D08378
|
Pioglitazone
| [17] 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
120 |
AVPR1A
| [4] Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D01236
D01236
|
Conivaptan
| [1] 86 86 |
121 |
AVPR1A
| [4] Calcium signaling pathway Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D07748
D07748
|
Conivaptan
| [1] 86 86 |
122 |
AVPR2
| [3] Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D01236
D01236
|
Conivaptan
| [1] 86 86 |
123 |
AVPR2
| [3] Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D07748
D07748
|
Conivaptan
| [1] 86 86 |
124 |
PRKAA1
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
125 |
PRKAA1
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
126 |
PRKAA2
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
127 |
PRKAA2
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
128 |
PRL
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D01348
D01348
|
Terguride
| [2] 51 51, 86 |
129 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D00106
D00106
|
Epoprostenol
| [1] 86 86 |
130 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D01337
D01337
|
Epoprostenol
| [1] 86 86 |
131 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D02720
D02720
|
Beraprost
| [1] 86 86 |
132 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D02721
D02721
|
Iloprost
| [4] 51 51, 84, 85, 86 |
133 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D06213
D06213
|
Treprostinil
| [6] 51 51, 84, 85, 86, 88, 210 |
134 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D09994
D09994
|
Selexipag
| [6] 47 47, 51, 70, 84, 86, 88 |
135 |
PTGIR
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation | D10725
D10725
|
Ralinepag
| [1] 86 86 |
136 |
PTGS1
| [5] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00109
D00109
|
Acetylsalicylic acid
| [15] 13 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251 |
137 |
PTGS1
| [5] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00217
D00217
|
Acetaminophen
| [18] 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
138 |
PTGS2
| [22] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00109
D00109
|
Acetylsalicylic acid
| [15] 13 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251 |
139 |
PTGS2
| [22] Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00217
D00217
|
Acetaminophen
| [18] 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
140 |
RAF1
| [83] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Cellular senescence, Vascular smooth muscle contraction, Axon guidance, VEGF signaling pathway, Apelin signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
141 |
RAF1
| [83] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Cellular senescence, Vascular smooth muscle contraction, Axon guidance, VEGF signaling pathway, Apelin signaling pathway, Focal adhesion, Gap junction, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, GnRH secretion, Growth hormone synthesis, secretion and action, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Salmonella infection, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
142 |
RET
| [5] Calcium signaling pathway Calcium signaling pathway, Pathways in cancer, Thyroid cancer, Non-small cell lung cancer, Central carbon metabolism in cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
143 |
RET
| [5] Calcium signaling pathway Calcium signaling pathway, Pathways in cancer, Thyroid cancer, Non-small cell lung cancer, Central carbon metabolism in cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
144 |
BRD2
| - | D11131
D11131
|
Apabetalone
| [1] 86 86 |
145 |
RRM2
| [6] Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, p53 signaling pathway | D00341
D00341
|
Hydroxyurea
| [8] 3 3, 13, 19, 20, 65, 85, 86, 284 |
146 |
SCN1A
| [1] Dopaminergic synapse Dopaminergic synapse | D00358
D00358
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
147 |
SCN1A
| [1] Dopaminergic synapse Dopaminergic synapse | D02086
D02086
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
148 |
SCN1A
| [1] Dopaminergic synapse Dopaminergic synapse | D08127
D08127
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
149 |
SCN2A
| [1] Taste transduction Taste transduction | D00358
D00358
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
150 |
SCN2A
| [1] Taste transduction Taste transduction | D02086
D02086
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
151 |
SCN2A
| [1] Taste transduction Taste transduction | D08127
D08127
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
152 |
SCN3A
| [1] Taste transduction Taste transduction | D00358
D00358
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
153 |
SCN3A
| [1] Taste transduction Taste transduction | D02086
D02086
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
154 |
SCN3A
| [1] Taste transduction Taste transduction | D08127
D08127
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
155 |
SCN5A
| [1] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D00358
D00358
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
156 |
SCN5A
| [1] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D02086
D02086
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
157 |
SCN5A
| [1] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D08127
D08127
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
158 |
SCN9A
| [1] Taste transduction Taste transduction | D00358
D00358
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
159 |
SCN9A
| [1] Taste transduction Taste transduction | D02086
D02086
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
160 |
SCN9A
| [1] Taste transduction Taste transduction | D08127
D08127
|
Lidocaine
| [6] 86 86, 107, 168, 226, 231, 256 |
161 |
P2RY12
| [1] Platelet activation Platelet activation | D00769
D00769
|
Clopidogrel
| [1] 86 86 |
162 |
P2RY12
| [1] Platelet activation Platelet activation | D07729
D07729
|
Clopidogrel
| [1] 86 86 |
163 |
P2RY12
| [1] Platelet activation Platelet activation | D10823
D10823
|
Clopidogrel
| [1] 86 86 |
164 |
P2RY12
| [1] Platelet activation Platelet activation | D10824
D10824
|
Clopidogrel
| [1] 86 86 |
165 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00326
D00326
|
Fluoxetine
| [6] 13 13, 17, 78, 86, 179, 206 |
166 |
SLC6A4
| [2] Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00823
D00823
|
Fluoxetine
| [6] 13 13, 17, 78, 86, 179, 206 |
167 |
BRAF
| [44] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer | D06272
D06272
|
Sorafenib
| [2] 34 34, 86 |
168 |
BRAF
| [44] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer | D08524
D08524
|
Sorafenib
| [2] 34 34, 86 |
169 |
BRDT
| - | D11131
D11131
|
Apabetalone
| [1] 86 86 |
170 |
TBXA2R
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation | D04500
D04500
|
Ifetroban
| [3] 51 51, 86, 113 |
171 |
VEGFA
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Pancreatic cancer, Bladder cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis | D06409
D06409
|
Bevacizumab
| [9] 13 13, 34, 85, 86, 87, 89, 227, 280, 331 |
172 |
TRPV1
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00250
D00250
|
Capsaicin
| [5] 2 2, 6, 19, 86, 226 |
173 |
CA1
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
174 |
CA1
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
175 |
CA2
| [7] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
176 |
CA2
| [7] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
177 |
CA3
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
178 |
CA3
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
179 |
CA4
| [3] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
180 |
CA4
| [3] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
181 |
CA5A
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
182 |
CA5A
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
183 |
CA6
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
184 |
CA6
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
185 |
CA7
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
186 |
CA7
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
187 |
CA8
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
188 |
CA8
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
189 |
CA9
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
190 |
CA9
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
191 |
CA12
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D00218
D00218
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
192 |
CA12
| [2] Nitrogen metabolism Nitrogen metabolism, Metabolic pathways | D01196
D01196
|
Acetazolamide
| [8] 13 13, 86, 90, 115, 154, 155, 225, 230 |
193 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00616
D00616
|
Diltiazem
| [3] 51 51, 58, 86 |
194 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00617
D00617
|
Nicardipine
| [2] 70 70, 86 |
195 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D03830
D03830
|
Diltiazem
| [3] 51 51, 58, 86 |
196 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| [3] 51 51, 58, 86 |
197 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| [2] 70 70, 86 |
198 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00616
D00616
|
Diltiazem
| [3] 51 51, 58, 86 |
199 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00617
D00617
|
Nicardipine
| [2] 70 70, 86 |
200 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D03830
D03830
|
Diltiazem
| [3] 51 51, 58, 86 |
201 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| [3] 51 51, 58, 86 |
202 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| [2] 70 70, 86 |
203 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00616
D00616
|
Diltiazem
| [3] 51 51, 58, 86 |
204 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00617
D00617
|
Nicardipine
| [2] 70 70, 86 |
205 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D03830
D03830
|
Diltiazem
| [3] 51 51, 58, 86 |
206 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| [3] 51 51, 58, 86 |
207 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| [2] 70 70, 86 |
208 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00616
D00616
|
Diltiazem
| [3] 51 51, 58, 86 |
209 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D00617
D00617
|
Nicardipine
| [2] 70 70, 86 |
210 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D03830
D03830
|
Diltiazem
| [3] 51 51, 58, 86 |
211 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D07845
D07845
|
Diltiazem
| [3] 51 51, 58, 86 |
212 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08270
D08270
|
Nicardipine
| [2] 70 70, 86 |
213 |
IL1R2
| [7] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis | D02934
D02934
|
Anakinra
| [19] 2 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 |
214 |
VKORC1
| [3] Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D00564
D00564
|
Warfarin
| [13] 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
215 |
VKORC1
| [3] Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D01280
D01280
|
Warfarin
| [13] 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
216 |
VKORC1
| [3] Ubiquinone and other terpenoid-quinone biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors | D08682
D08682
|
Warfarin
| [13] 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
217 |
BRD3
| - | D11131
D11131
|
Apabetalone
| [1] 86 86 |
218 |
TAS1R2
| [2] Taste transduction Taste transduction, Carbohydrate digestion and absorption | D02381
D02381
|
Aspartame
| [5] 6 6, 13, 67, 86, 230 |
219 |
TAS1R3
| [2] Taste transduction Taste transduction, Carbohydrate digestion and absorption | D02381
D02381
|
Aspartame
| [5] 6 6, 13, 67, 86, 230 |
220 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02008
D02008
|
Tadalafil
| [7] 6 6, 51, 75, 84, 86, 113, 210 |
221 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02229
D02229
|
Sildenafil
| [17] 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
222 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02731
D02731
|
Vardenafil
| [3] 13 13, 86, 299 |
223 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D03260
D03260
|
Vardenafil
| [3] 13 13, 86, 299 |
224 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D08514
D08514
|
Sildenafil
| [17] 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
225 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D08668
D08668
|
Vardenafil
| [3] 13 13, 86, 299 |
226 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D10027
D10027
|
Udenafil
| [2] 86 86, 210 |
227 |
CACNA1I
| [7] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D01303
D01303
|
Flunarizine
| [4] 58 58, 86, 149, 215 |
228 |
CACNA1I
| [7] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D07971
D07971
|
Flunarizine
| [4] 58 58, 86, 149, 215 |
229 |
CACNA1H
| [7] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D01303
D01303
|
Flunarizine
| [4] 58 58, 86, 149, 215 |
230 |
CACNA1H
| [7] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D07971
D07971
|
Flunarizine
| [4] 58 58, 86, 149, 215 |
231 |
CACNA1G
| [8] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome | D01303
D01303
|
Flunarizine
| [4] 58 58, 86, 149, 215 |
232 |
CACNA1G
| [8] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome | D07971
D07971
|
Flunarizine
| [4] 58 58, 86, 149, 215 |
233 |
ACVR2A
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | D09670
D09670
|
Sotatercept
| [2] 86 86, 284 |
234 |
MS4A1
| [1] Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| [19] 86 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
235 |
KEAP1
| [6] Ubiquitin mediated proteolysis Ubiquitin mediated proteolysis, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis | D03846
D03846
|
Dimethyl fumarate
| [5] 13 13, 49, 51, 86, 296 |